Market Analysis Study for Countervail’s Novel Diagnostic Test Technology July 16, 2019 • Bill Basinger • Uncategorized Read More »
Countervail receives additional $845,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. May 29, 2015 • admin • Funding, General News, Military, Pharmaceuticals, Uncategorized Read More »
Countervail Corporation is awarded a $5.3 million contract by the Biomedical Advanced Research and Development Authority September 15, 2011 • admin • Uncategorized Read More »
Countervail wins business plan competition at 8th annual Five Ventures conference. Out of 130 competing companies, Countervail wins the Biotechnology – Pharmaceutical division for best business plan presentation. April 30, 2009 • admin • General News, Uncategorized Read More »